A Legal Storm Brews: Sarepta's Groundbreaking Muscular Dystrophy Therapy Faces Renewed Patent Challenge
Why Did Regenxbio (RGNX) Shares Take Such a Steep Dive After Hours? Unpacking the Gene Therapy News
Navigating the Path to Approval: Why REGENXBIO (RGNX) Remains a Strong Investment with RGX-121 for Hunter Syndrome